mepolizumab   Click here for help

GtoPdb Ligand ID: 7685

Synonyms: Nucala® | SB-240563
Approved drug Immunopharmacology Ligand
mepolizumab is an approved drug (EMA & FDA (2015))
Compound class: Antibody
Comment: The Nucala® brand of mepolizumab is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: mepolizumab

No information available.
Summary of Clinical Use Click here for help
Mepolizumab is approved for the treatment of severe asthma in patients who are already taking other asthma medications [2,8].
In the United States and the European Union, mepolizumab can be used under orphan drug designation for the treatment of Churg-Strauss syndrome and hypereosinophilic syndrome.
Click here to link to's full list of mepolizumab trials, including ongoing trials in additional eosinophilic conditions.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Mepolizumab antagonises IL-5 activity by effectively neutralising circulating IL-5. This leads to a reduction in eosinophil numbers in blood, tissue and sputum [3,7] and this effect underlies the drug's anti-inflammatory action [6,9].
External links Click here for help